Home › Funds › Skandinaviska Enskilda Banken AB (publ) › VRTX

Skandinaviska Enskilda Banken AB (publ) position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Skandinaviska Enskilda Banken AB (publ) reported holding 23,000 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$12.0M, representing 0.44% of its reported portfolio and ranking #22 among its reported holdings. Skandinaviska Enskilda Banken AB (publ) has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)23.00K sh
Reported value held$12.02M
Portfolio Weight0.44%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Skandinaviska Enskilda Banken AB (publ)'s VRTX position evolved

Skandinaviska Enskilda Banken AB (publ) first disclosed a stake in VRTX in Q3 2023 at 326,630 shares (US$113.6M). Across 13 filings, Skandinaviska Enskilda Banken AB (publ) increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 23,000 shares valued at US$12.0M. Notable position changes include a 25% trim in Q4 2023 (shares rose 2% over the following quarter), a 74% trim in Q1 2026 (shares rose 11% over the following quarter), a 50% trim in Q2 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 326.63K $113.63M New
Q4 2023 243.74K $99.26M Reduce
Q1 2024 264.92K $110.82M Add
Q2 2024 218.83K $102.51M Reduce
Q3 2024 185.28K $86.19M Reduce
Q4 2024 171.03K $68.30M Reduce
Q1 2025 186.47K $90.36M Add
Q2 2025 176.60K $78.65M Reduce
Q3 2025 154.25K $60.39M Reduce
Q4 2025 174.47K $79.10M Add
Q1 2026 46.00K $20.54M Reduce
Q2 2026 23.00K $11.42M Reduce
Q3 2026 23.00K $12.02M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Skandinaviska Enskilda Banken AB (publ) held VRTX?

Skandinaviska Enskilda Banken AB (publ) has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Skandinaviska Enskilda Banken AB (publ)'s current position in VRTX?

As of Q3 2026, Skandinaviska Enskilda Banken AB (publ) holds 23.00K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $12.02M, representing 0.44% of its reported portfolio and ranking #22.

Has Skandinaviska Enskilda Banken AB (publ) been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Skandinaviska Enskilda Banken AB (publ) held unchanged its position in VRTX.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.